Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Genotypic resistance testing in routine clinical care

Genotypic resistance testing in routine clinical care a a b David T. Dunn , Kate Coughlin and Patricia A. Cane a b MRC Clinical Trials Unit and Health Protection Purpose of review Agency, London, UK Genotypic resistance testing has become part of routine clinical management of HIV- Correspondence to David T. Dunn, MRC Clinical Trials infected patients. Focussing on observational studies, this review looks at recent Unit, 222 Euston Road, London, NW1 2DA, UK advances in this area. Tel: +44 20 7670 4739; e-mail: d.dunn@ctu.mrc.ac.uk Recent findings Current Opinion in HIV and AIDS 2011, Translation of the nucleotide sequence generated by the resistance test into clinically 6:251–257 useful information remains a major challenge. A recent key development is the availability of therapy optimization tools to predict regimens that are most likely to achieve virological suppression. Standard genotypic resistance testing only examines protease and part of reverse transcriptase; as drugs are licensed to further targets, it has become necessary to expand the repertoire for testing. Traditionally, genotypic testing has not been attempted at viral loads less than 1000 copies/ml, but recent studies indicate that major mutations are often detected at much lower levels. Similarly, various methods have been developed for the detection of minority variants including allele- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Genotypic resistance testing in routine clinical care

Cane, Patricia A
Current Opinion in HIV and Aids , Volume 6 (4) – Jul 1, 2011
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/genotypic-resistance-testing-in-routine-clinical-care-0XqvrvNtw9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e32834732e8
pmid
21646877
Publisher site
See Article on Publisher Site

Abstract

a a b David T. Dunn , Kate Coughlin and Patricia A. Cane a b MRC Clinical Trials Unit and Health Protection Purpose of review Agency, London, UK Genotypic resistance testing has become part of routine clinical management of HIV- Correspondence to David T. Dunn, MRC Clinical Trials infected patients. Focussing on observational studies, this review looks at recent Unit, 222 Euston Road, London, NW1 2DA, UK advances in this area. Tel: +44 20 7670 4739; e-mail: d.dunn@ctu.mrc.ac.uk Recent findings Current Opinion in HIV and AIDS 2011, Translation of the nucleotide sequence generated by the resistance test into clinically 6:251–257 useful information remains a major challenge. A recent key development is the availability of therapy optimization tools to predict regimens that are most likely to achieve virological suppression. Standard genotypic resistance testing only examines protease and part of reverse transcriptase; as drugs are licensed to further targets, it has become necessary to expand the repertoire for testing. Traditionally, genotypic testing has not been attempted at viral loads less than 1000 copies/ml, but recent studies indicate that major mutations are often detected at much lower levels. Similarly, various methods have been developed for the detection of minority variants including allele-

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jul 1, 2011

There are no references for this article.